BioMarin Pharma (BMRN) Tops Q3 EPS by 23c; offers guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 +2.21%
Revenue Growth %: +13.2%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.46, $0.23 better than the analyst estimate of $0.23. Revenue for the quarter came in at $581.3 million versus the consensus estimate of $607.5 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.90-$2.05, versus the consensus of $2.19. BioMarin Pharma sees FY2023 revenue of $2390-2470 million, versus the consensus of $2449 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AXT appoints Tracy Liu to its board of directors
- Hermès can regain momentum despite China weakness, Jefferies says
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
